Abstract
The tuberous sclerosis complex (TSC1/TSC2/TBC1D7) primarily functions to inhibit the mechanistic target of rapamycin complex 1 (mTORC1), a crucial regulator of cell growth. Mutations in TSC1 or TSC2 cause tuberous sclerosis complex (TSC), a rare autosomal dominant genetic disorder marked by benign tumors in multiple organs that rarely progress to malignancy. Traditionally, TSC proteins are considered tumor suppressive due to their inhibition of mTORC1 and other mechanisms. However, more recent studies have shown that TSC proteins can also promote tumorigenesis in certain cancer types. In this review, we explore the composition and function of the TSC protein complex, the roles of its individual components in cancer biology, and potential future therapeutic targeting strategies.
| Original language | English |
|---|---|
| Pages (from-to) | 452-465 |
| Number of pages | 14 |
| Journal | Trends in Molecular Medicine |
| Volume | 31 |
| Issue number | 5 |
| Early online date | 1-Nov-2024 |
| DOIs | |
| Publication status | Published - May-2025 |
Fingerprint
Dive into the research topics of 'The dual role of the TSC complex in cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver